USD
$0.00
(0.00%
)At Close (As of Sep 17, 2025)
$46.04B
Market Cap
38.31
P/E Ratio
19.64
EPS
$779.03
52 Week High
$510.06
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $2B |
Total Revenue | $2.2B |
Cost Of Revenue | $227M |
Costof Goods And Services Sold | $227M |
Operating Income | -$22M |
Selling General And Administrative | $745M |
Research And Development | $983M |
Operating Expenses | $1.1B |
Investment Income Net | - |
Net Interest Income | $136M |
Interest Income | $139M |
Interest Expense | $2.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $18M |
Income Before Tax | $85M |
Income Tax Expense | -$748M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $833M |
Comprehensive Income Net Of Tax | - |
Ebit | $88M |
Ebitda | $105M |
Net Income | $833M |
Field | Value (USD) |
---|---|
Total Assets | $6.2B |
Total Current Assets | $4.9B |
Cash And Cash Equivalents At Carrying Value | $1.5B |
Cash And Short Term Investments | $1.5B |
Inventory | $407M |
Current Net Receivables | $909M |
Total Non Current Assets | $1.3B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $181M |
Intangible Assets Excluding Goodwill | $181M |
Goodwill | $6.3M |
Investments | - |
Long Term Investments | $50M |
Short Term Investments | $1.9B |
Other Current Assets | $188M |
Other Non Current Assets | - |
Total Liabilities | $704M |
Total Current Liabilities | $670M |
Current Accounts Payable | $483M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $13M |
Total Non Current Liabilities | $34M |
Capital Lease Obligations | $39M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $39M |
Other Current Liabilities | $161M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $5.5B |
Treasury Stock | - |
Retained Earnings | -$1.6B |
Common Stock | $7M |
Common Stock Shares Outstanding | $65M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$83M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $18M |
Capital Expenditures | $68M |
Change In Receivables | - |
Change In Inventory | -$96M |
Profit Loss | - |
Cashflow From Investment | -$718M |
Cashflow From Financing | $280M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$22M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $833M |
Field | Value (USD) |
---|---|
Gross Profit | $2B |
Total Revenue | $2.2B |
Cost Of Revenue | $227M |
Costof Goods And Services Sold | $227M |
Operating Income | -$22M |
Selling General And Administrative | $745M |
Research And Development | $983M |
Operating Expenses | $1.1B |
Investment Income Net | - |
Net Interest Income | $136M |
Interest Income | $139M |
Interest Expense | $2.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $18M |
Income Before Tax | $85M |
Income Tax Expense | -$748M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $833M |
Comprehensive Income Net Of Tax | - |
Ebit | $88M |
Ebitda | $105M |
Net Income | $833M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.